A series of randomised, doubleblind controlled trials have consistently shown that, in patients already on a diuretic, the addition of an angiotensin-converting enzyme (ACE) inhibitor significantly improves symptoms and signs of chronic heart failure and increases survival. 1, 2 Recently, angiotensin II (AII) receptor blockers have been introduced in the treatment of hypertension, and heart failure. 3 An important clinical question is whether in patients already on an optimum dose of an ACE inhibitor, further blockade of the renin-angiotensin system using a specific AII type I receptor antagonist (losartan) has additive effects in severe heart failure. We studied the clinical and hormonal effects of AII type 1 receptor inhibition in a patient with severe heart failure who was already on treatment with an ACE inhibitor and a diuretic. The study was approved by the hospital ethical committee.
A 51-year-old Asian man with a long history of well controlled hypertension, diet controlled hyperlipidaemia, non-Q wave and anterior myocardial infarctions (1989 and 1996 respectively) was admitted to hospital with symptoms and signs of severe biventricular cardiac failure. Prior to hospital admission the patient was reviewed weekly in the Blood Pressure Unit. Both the ACE inhibitor therapy and the diuretic treatment was increased 2 weeks prior to admission. Lisinopril was increased from 10 mg to 20 mg b. pressure was 95/66 mm Hg and the heart rate was 102 bpm and regular. The jugular venous pressure was raised to 6 cm, he had a third heart sound and bilateral basal lung crepitations. The Boston heart failure score was 11/12. 4 Serum sodium was 140 mmol/l, potassium 4.1 mmol/l, creatinine 129 mol/l and cholesterol 5.7 mmol/l. Three-dimensional echocardiography 5 revealed apical akinesia with severe impairment in systolic function (ejection fraction 15%).
The patient continued the same drug regime as previously. Prior to the study his sodium intake was approximately 130 mmols a day. After 4 days of bed rest, losartan 25 mg b.d. was added for 1 week (day 0 to day 7). Throughout the study period (day −4 to day +8) he was maintained on a constant sodium intake of 100 mmols a day (diet of 30 mmols, supplemented with seven slow Sodium tablets each containing 10 mmols of sodium chloride). Twenty-four hour urinary collections were performed for measurement of volume and electrolytes. Blood was collected on admission and periodically throughout the study for measurement of plasma renin activity (PRA), aldosterone, atrial natriuretic peptide (ANP) and angiotensin II levels.
Following the addition of losartan there was no improvement in the patient's symptoms or signs, no change in left ventricular ejection fraction (as assessed by threedimensional echocardiography), and in particular no change in blood pressure which remained at the same levels throughout the study. However, during the 1 week's treatment with losartan there was an increase in weight by 3.1 kg (Figure 1) , with evidence from the urinary sodium excretion that this was probably due to retention of sodium and water. Plasma ANP was high on admission at 237 pg/ml (normal range 1-16 pg/ml) and rose slightly during the 1 week's treatment with losartan to 292 pg/ml (day 7). Plasma angiotensin II was low before the addition of losartan at 1.0 pg/ml (normal range 2-12 pg/ml) and remained at these levels throughout the study apart from a rise at 24 h after initiating losartan to 9.8 pg/ml, but by the second day had fallen back to the levels as before starting treatment. Plasma aldosterone showed no trend, in particular it was not suppressed by the addition of losartan ( Figure 1 ). Plasma renin activity increased following treatment with losartan and appeared to fall after stopping the above drug (Figure 1 ). Serum creatinine was 120 mol/L on day 7.
There has been much speculation that angiotensin II receptor antagonists may have an additive effect in patients with severe heart failure already on an ACE inhibitor. Our patient however, clearly demonstrates that, at least acutely for 7 days, there was no obvious improvement in clinical signs or symptoms and if anything a deterioration in sodium and water balance. Furthermore, there was no fall in plasma ANP, no consistent change in plasma aldosterone, and no fall in blood pressure. This would appear to indicate that, at least in this setting, the angiotensin antagonist losartan does not have any immediate effect. Nevertheless, the rise in plasma renin activity and perhaps the transient rise in angiotensin II does indicate that the negative feedback on renin release from the juxta-glomerular apparatus can be enhanced by the addition of losartan to an ACE inhibitor and does indicate that at least in this respect the blockade of the renin system by lisinopril 20 mg b.d. was not complete.
Clearly our study was only a short-term one and it could well be that the long-term use of an angiotensin II receptor antagonist added to an ACE inhibitor may have other beneficial effects in patients with congestive heart failure. Indeed, recent data suggest that peak aerobic capacity during symptom limited treadmill exercise, and NYHA functional class improve in some though not all patients with heart failure after 6 months of treatment with an ACE inhibitor and an angiotensin II receptor antagonist. 6 However importantly our patient was on lisinopril 20 mg b.d. Many of the on-going studies looking at the long-term benefits of adding losartan are using inadequate amounts of an ACE inhibitor. In this situation it is not surprising that the addition of an AII recepter blocker would have an additive effect. 
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